Routine annual meeting results — no immediate trading catalyst. Monitor for any subsequent capital raise or share issuance under the newly increased authorized capital.
Price Chart
Executive Summary
Chemomab Therapeutics filed a 6-K reporting results of its annual general meeting held on May 5, 2026. Shareholders approved the re-election of directors, compensation policy, an increase in authorized share capital, and reappointment of auditors. This is routine governance with no material financial impact.
Key Facts
- Re-elected Neil Cohen and Dr. Claude Nicaise as Class II directors
- Approved compensation policy for office holders and directors
- Approved increase in authorized share capital and amended articles accordingly
- Re-appointed Somekh Chaikin (KPMG) as independent auditor for FY2026
Financial Impact
No material financial impact; authorized share increase allows future capital raises but no immediate dilution
Risk Factors
- Potential future dilution from increased authorized capital if shares are issued
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002423 |
| Document: 0001178913-26-002423-index-headers.html | 0001178913-26-002423 |
| Document: 0001178913-26-002423-index.html | 0001178913-26-002423 |
| Document: 0001178913-26-002423.txt | 0001178913-26-002423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access